Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer
- 2 December 2010
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 363 (23) , 2200-2210
- https://doi.org/10.1056/nejmoa0910320
Abstract
A regimen of docetaxel, doxorubicin, and cyclophosphamide (TAC) is superior to a regimen of fluorouracil, doxorubicin, and cyclophosphamide (FAC) when used as adjuvant therapy in women with node-positive breast cancer. The value of taxanes in the treatment of node-negative disease has not been determined.Keywords
This publication has 20 references indexed in Scilit:
- Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735Journal of Clinical Oncology, 2009
- Randomized Phase 3 Trial of Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast CancerJNCI Journal of the National Cancer Institute, 2008
- Weekly Paclitaxel in the Adjuvant Treatment of Breast CancerNew England Journal of Medicine, 2008
- Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized TrialsJournal of Clinical Oncology, 2008
- Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 TrialJournal of Clinical Oncology, 2006
- Phase III Trial Comparing Doxorubicin Plus Cyclophosphamide With Docetaxel Plus Cyclophosphamide As Adjuvant Therapy for Operable Breast CancerJournal of Clinical Oncology, 2006
- Benefit of taxanes as adjuvant chemotherapy for early breast cancerCancer, 2006
- Adjuvant Docetaxel for Node-Positive Breast CancerNew England Journal of Medicine, 2005
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast CancerJournal of Clinical Oncology, 2003